NasdaqCM:VRDNBiotechs
The Bull Case For Viridian Therapeutics (VRDN) Could Change Following FDA Approval Of Lumvoa For Thyroid Eye Disease
Viridian Therapeutics recently reported that the U.S. Food and Drug Administration approved Lumvoa (veligrotug-vvze), an intravenous IGF-1R antagonist, for the treatment of thyroid eye disease, covering both active and chronic forms based on the THRIVE and THRIVE-2 phase 3 trials.
This approval not only gives Viridian its first commercial product but also introduces the first TED therapy with labeling that includes data for both disease stages and statistically significant effects on...